|
In vivo compound treatments used in training and testing |
|||||
| Compound |
Class |
Conducted by |
Dose (mpk) |
Necropsy day |
Vehicle – Route |
|
|
|||||
| Cisplatin |
DNA – alkylator |
Merck |
0.5 |
3, 8 |
0.9% (w/v) sodium chloride – IP |
| 3.5 |
3, 8 |
||||
| 7 |
3, 8 |
||||
| Cyclosporin A |
Calcineurin inhibitor |
Merck |
6 |
3, 9, 15 |
olive oil – SC |
| 30 |
3, 9, 15 |
||||
| 60 |
3, 9, 15 |
||||
| Gentamycin |
Antibiotic |
Merck |
20 |
3, 9, 15 |
0.9% (w/v) sodium chloride – IP |
| 80 |
3, 9, 15 |
||||
| 240 |
3, 9, 12 |
||||
| Sodium Fluoride |
Environmental toxin |
Merck |
35 |
3, 8, 12 |
Water – PO |
| 75 |
3, 8, 12 |
||||
| Merck X |
Antibiotic |
Merck |
75 |
3, 8, 14 |
0.5%saline – IV |
| 150 |
3, 8, 14 |
||||
| 225 |
3, 8 |
||||
| Allopurinol |
Xanthine oxidase inhibitor |
Charles River |
6 |
3 |
corn oil – IP |
| 30 |
3 |
||||
| 100 |
3, 7, 14 |
||||
| D-serine |
Serine analog |
Charles River |
750 |
3, 14 |
water – IP |
| Hexachloro 1,3, butadiene |
Synthetic toxin |
Charles River |
7.5 |
3 |
corn oil – IP |
| 40 |
3, 14 |
||||
| 100 |
3 |
||||
| Puromycin |
Antibiotic |
Charles River |
5 |
3 |
0.9% (w/v) sodium chloride – IP |
| 20 |
3, 7, 14 |
||||
| 60 |
3, 7 |
||||
| Tobramycin |
Antibiotic |
Charles River |
6 |
3 |
0.9% (w/v) sodium chloride – IP |
| 30 |
14 |
||||
| 60 |
3, 14 |
||||
|
Male Sprague-Dawley rats were treated daily with the listed compounds except D-serine which was given as a single dose once on day 0. Each dose group includes 4 or 5 rats. Animals were terminated at the end of study. Terminal or interim necropsy were performed 24 hours post dosing. Kidney expression profiles were obtained for each necropsy day (when kidney samples were harvested). Appropriate dosing routes were applied: PO – Oral Garvage, IV – intravenous, SC – subcutaneous. | |||||
Jiang et al. Journal of Translational Medicine 2007 5:47 doi:10.1186/1479-5876-5-47 |
|||||